Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Molimard

Showing results (151-160 of 170) with videos related to

Pageof 17
Sort By:
Therapie|December 19, 2023
What should be done to combat misinformation about health products?Joëlle Micallef, Hervé Maisonneuve, Sophie Muller, et al.
Therapie|January 26, 2022
Prevention of risks associated with inappropriate use/unnecessary consumption of medicinesJean-Luc Cracowski, Sophie Muller, Isabelle Anglade, et al.
Therapie|November 20, 2023
Joëlle Micallef, Hervé Maisonneuve, Sophie Muller, et al.
Therapie|January 24, 2022
Jean-Luc Cracowski, Sophie Muller, Isabelle Anglade, et al.
Therapie|January 10, 2026
How can the level of health product education (literacy) be raised among the general public?Clara Locher, Nathalie Manaud, Mathieu Molimard, et al.
The Journal of Clinical Investigation|August 3, 2016
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertensionChristophe Guignabert, Carole Phan, Andrei Seferian, et al.
Therapie|January 10, 2026
Clara Locher, Nathalie Manaud, Mathieu Molimard, et al.
The Lancet. Oncology|April 13, 2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trialOlivier Mir, Claire Cropet, Maud Toulmonde, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 14, 2020
Spacers and Valved Holding Chambers-The Risk of Switching to Different ChambersFederico Lavorini, Celeste Barreto, Job F M van Boven, et al.
Blood|February 25, 2011
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyAmr R Ibrahim, Lina Eliasson, Jane F Apperley, et al.
Pageof 17

Showing results (151-160 of 170) with videos related to

Sort By:
Pageof 17
Therapie|December 19, 2023
What should be done to combat misinformation about health products?Joëlle Micallef, Hervé Maisonneuve, Sophie Muller, et al.
Therapie|January 26, 2022
Prevention of risks associated with inappropriate use/unnecessary consumption of medicinesJean-Luc Cracowski, Sophie Muller, Isabelle Anglade, et al.
Therapie|November 20, 2023
Joëlle Micallef, Hervé Maisonneuve, Sophie Muller, et al.
Therapie|January 24, 2022
Jean-Luc Cracowski, Sophie Muller, Isabelle Anglade, et al.
Therapie|January 10, 2026
How can the level of health product education (literacy) be raised among the general public?Clara Locher, Nathalie Manaud, Mathieu Molimard, et al.
The Journal of Clinical Investigation|August 3, 2016
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertensionChristophe Guignabert, Carole Phan, Andrei Seferian, et al.
Therapie|January 10, 2026
Clara Locher, Nathalie Manaud, Mathieu Molimard, et al.
The Lancet. Oncology|April 13, 2016
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trialOlivier Mir, Claire Cropet, Maud Toulmonde, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 14, 2020
Spacers and Valved Holding Chambers-The Risk of Switching to Different ChambersFederico Lavorini, Celeste Barreto, Job F M van Boven, et al.
Blood|February 25, 2011
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyAmr R Ibrahim, Lina Eliasson, Jane F Apperley, et al.
Pageof 17